Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AYTUNASDAQ:CTXRNASDAQ:EVAXNASDAQ:TRAW On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAYTUAytu BioPharma$2.03-0.5%$1.62$0.95▼$2.97$18.22M0.05746,411 shs73,176 shsCTXRCitius Pharmaceuticals$1.44+11.6%$0.85$0.65▼$26.25$15.15M0.87688,459 shs1.41 million shsEVAXEvaxion A/S$2.45$1.99$1.20▼$17.75$3.43M0.1613,508 shs22,233 shsTRAWTraws Pharma$1.48-3.6%$1.52$0.97▼$19.44$8.20M1.48445,362 shs221,255 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAYTUAytu BioPharma+3.03%+3.55%+4.08%+65.18%-30.85%CTXRCitius Pharmaceuticals+25.24%+51.18%+83.50%-5.15%-91.91%EVAXEvaxion A/S+0.41%+18.36%+30.32%+38.42%-81.44%TRAWTraws Pharma-1.29%-7.83%+16.79%-39.53%+152,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAYTUAytu BioPharma1.3451 of 5 stars0.04.00.03.42.50.00.6CTXRCitius Pharmaceuticals2.1015 of 5 stars3.42.00.00.01.10.81.3EVAXEvaxion A/S1.6775 of 5 stars3.52.00.00.01.11.70.0TRAWTraws Pharma0.2339 of 5 stars0.03.00.00.01.10.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAYTUAytu BioPharma 0.00N/AN/AN/ACTXRCitius Pharmaceuticals 2.80Moderate Buy$54.503,684.72% UpsideEVAXEvaxion A/S 3.00Buy$10.00308.16% UpsideTRAWTraws Pharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest EVAX, AYTU, TRAW, and CTXR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/9/2025CTXRCitius PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.005/23/2025CTXRCitius PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold5/23/2025CTXRCitius PharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/15/2025CTXRCitius PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.004/2/2025EVAXEvaxion A/SHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.00(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAYTUAytu BioPharma$81M0.22N/AN/A$4.64 per share0.44CTXRCitius PharmaceuticalsN/AN/AN/AN/A$10.25 per shareN/AEVAXEvaxion A/S$3.34M1.03N/AN/A($1.18) per share-2.08TRAWTraws Pharma$230K35.66N/AN/A($8.66) per share-0.17Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAYTUAytu BioPharma-$15.84M-$0.72N/A∞N/A2.37%3.51%0.91%N/ACTXRCitius Pharmaceuticals-$39.14MN/A0.001.15N/AN/A-58.63%-37.67%8/11/2025 (Estimated)EVAXEvaxion A/S-$10.57M-$1.16N/AN/AN/A-316.03%-532.72%-78.32%8/13/2025 (Estimated)TRAWTraws Pharma-$166.52M-$32.81N/AN/AN/A-15,245.81%N/A-193.21%8/13/2025 (Estimated)Latest EVAX, AYTU, TRAW, and CTXR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/27/2025Q1 2025EVAXEvaxion A/S-$0.65-$0.29+$0.36-$0.29$0.06 millionN/A5/15/2025Q1 2025TRAWTraws Pharma-$8.04$2.09+$10.13$2.09$0.06 million$0.06 million5/14/2025Q3 2025AYTUAytu BioPharma-$0.17$0.20+$0.37$0.21$13.74 million$18.45 million5/14/2025Q2 2025CTXRCitius Pharmaceuticals-$1.08-$1.27-$0.19-$1.27N/AN/A4/1/2025Q4 2024EVAXEvaxion A/S-$0.26-$0.07+$0.19-$0.07$1.66 million$0.12 million3/31/2025Q4 2024 & Study UpdateTRAWTraws Pharma-$7.00$95.66+$102.66$95.66$0.06 million$0.06 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAYTUAytu BioPharmaN/AN/AN/AN/AN/ACTXRCitius PharmaceuticalsN/AN/AN/AN/AN/AEVAXEvaxion A/SN/AN/AN/AN/AN/ATRAWTraws PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAYTUAytu BioPharma0.271.030.87CTXRCitius PharmaceuticalsN/A0.370.06EVAXEvaxion A/SN/A2.012.01TRAWTraws PharmaN/A1.811.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAYTUAytu BioPharma33.49%CTXRCitius Pharmaceuticals16.88%EVAXEvaxion A/S11.04%TRAWTraws Pharma7.95%Insider OwnershipCompanyInsider OwnershipAYTUAytu BioPharma3.60%CTXRCitius Pharmaceuticals10.70%EVAXEvaxion A/S41.64%TRAWTraws Pharma13.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAYTUAytu BioPharma1608.98 million8.65 millionNot OptionableCTXRCitius Pharmaceuticals2010.63 million9.50 millionOptionableEVAXEvaxion A/S601.40 million819,000No DataTRAWTraws Pharma175.56 million4.81 millionOptionableEVAX, AYTU, TRAW, and CTXR HeadlinesRecent News About These CompaniesTraws Pharma Announces Promising Clinical Data for Rigosertib in Rare CancerJune 5, 2025 | msn.comTraws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug RigosertibJune 3, 2025 | globenewswire.comTraws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic PreparednessMay 27, 2025 | globenewswire.comTraws Pharma Unveils New Strategic Antiviral FocusMay 19, 2025 | tipranks.comTraws Pharma Highlights Q1 2025 Financial Progress and Antiviral DevelopmentsMay 18, 2025 | msn.comTraws Pharma Reports First Quarter 2025 Results and Business HighlightsMay 15, 2025 | globenewswire.comTraws Pharma Appoints New Chairman Amid Leadership ChangesApril 18, 2025 | tipranks.comThe Escalator: HHS, Spectrum Science, Alvotech and moreApril 3, 2025 | mmm-online.comTraws Pharma Reports 2024 Financial Results and Advances Bird Flu and COVID ProgramsApril 2, 2025 | msn.comTraws Pharma reports FY24 EPS ($35.21)April 1, 2025 | markets.businessinsider.comTraws Pharma, Inc. (TRAW) Virtual Investor Event TranscriptApril 1, 2025 | seekingalpha.comTraws Pharma, Inc.: Traws Pharma Reports Full Year 2024 Results and Business HighlightsMarch 31, 2025 | finanznachrichten.deTraws Pharma Reports Full Year 2024 Results and Business HighlightsMarch 31, 2025 | markets.businessinsider.comTraws Pharma Announces CEO Transition as Werner Cautreels RetiresMarch 30, 2025 | msn.comTraws Pharma, Inc.: Traws Pharma Announces Management UpdatesMarch 29, 2025 | finanznachrichten.deTraws Pharma: Werner Cautreels to Retire as CEO, While Continuing as a Bd Member >TRAWMarch 29, 2025 | marketwatch.comTraws Pharma: Werner Cautreels to Retire as CEO, While Continuing as a Bd Member >TRAWMarch 29, 2025 | marketwatch.comTraws Pharma Announces Virtual Investor Event to Showcase Innovative Treatments for Bird Flu and COVID-19March 29, 2025 | msn.comTraws Pharma CEO Werner Cautreels retires, Iain Dukes named interim CEOMarch 29, 2025 | markets.businessinsider.comTraws Pharma Announces Management UpdatesMarch 28, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEVAX, AYTU, TRAW, and CTXR Company DescriptionsAytu BioPharma NASDAQ:AYTU$2.03 -0.01 (-0.54%) As of 11:35 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.Citius Pharmaceuticals NASDAQ:CTXR$1.44 +0.15 (+11.63%) As of 11:35 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.Evaxion A/S NASDAQ:EVAX$2.45 0.00 (0.00%) As of 11:32 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.Traws Pharma NASDAQ:TRAW$1.48 -0.06 (-3.59%) As of 11:35 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Costco at a Crossroads: Is the Next Move Higher or Lower? AST SpaceMobile's Signal Strengthens as Stock Nears Orbit Oracle Stock Boils Higher, $300 Price Target in Sight 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Which Analyst-Favorite Drone Stock Will Come Out on Top? Why Qualcomm’s Latest Price Target Can't Be Ignored Texas Instruments Stock: Congress Likes It, Should You Too? Geospace Stock Skyrockets After Major Petrobras Contract Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
